| Antigen: |
CD74 (HLA-DR associated invariant chain) |
| Relevance: |
CD74 (HLA-DR-associated invariant chain) plays a role in antigen presentation. In addition to its expression on antigen-presenting cells, CD74 is expressed by carcinomas of renal, lung, gastric, and thymic origin and by certain sarcomas. The restricted expression of CD74 by normal tissues and its very rapid internalization make CD74 an attractive therapeutic target for both cancer and immunologic diseases. It has also been shown to have value as a gastric carcinoma marker |
| Clone: |
By2 |
| Subclass: |
IgG1 |
| Applications: |
Western blot, Immunohistochemistry (frozen and paraffin sections), FACS |
| Immunogen: |
B cell lymphoma cells |
| Reactivity: |
Human |
| Species raised in: |
Mouse |
| Fusion partner: |
NS-1 |
| Recommended growth conditions: |
RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT |
| References: |
Jones M, Pulford K, Micklem K, Mason DY (1995) Workshop mAb B029 (By2) - a new B-cell marker for use in diagnostic pathology. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 1, Oxford University Press, Oxford, New York and Tokyo, p 710-711
CD Guide for CD74 (2002) In Mason D. et al (eds) Leucocyte Typing VII, Oxford University Press, Oxford and New York, p 825-826 |
| Notes: |
Please note this cell line has not been weaned out of HAT. Ultroser G can be used at 1% if the cells are not growing well |
For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Click here to view Notes and Disclaimer information |
